Biogen and Ionis Expand Collaboration to Develop Therapy Candidates for Alzheimer’s, Other Neurological Diseases

Biogen and Ionis Expand Collaboration to Develop Therapy Candidates for Alzheimer’s, Other Neurological Diseases
Biogen and Ionis Pharmaceuticals are expanding their strategic collaboration through a new 10-year agreement to develop novel RNA-targeted therapy candidates for a broad range of neurological diseases, including Alzheimer’s disease. This agreement builds on the collaboration that produced Spinraza (nusinersen), the first and only approved treatment for spinal muscular dystrophy (SMA), and capitalizes on Biogen’s

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Richard Fenn says:

    Are there any markers for the presence of the tau protein in the blood or in the cerebrospinal fluid?

Leave a Comment

Your email address will not be published. Required fields are marked *